NMN and Leucomethylene Blue Composition for Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging is inevitable and an effective method of cell reprogramming to reverse aging remains an elusive goal due to epigenetic changes that lead to aberrant gene expression and genomic instability.
Innovation Solution
A composition comprising β-nicotinamide mononucleotide, trichostatin A, and zwitterionic liposomes, combined with reprogramming agents such as Oct-4, Sox 2, and Klf4, is used to reprogram cells to an embryonic state, enhancing epigenetic rejuvenation and promoting tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cell reprogramming methods are used, then some epigenetic changes may be reversed, but the process is inefficient and cannot fully restore youthful cellular function
Solution Approach 1:
The patent segments the reprogramming process by dividing epigenetic modifications into distinct types (DNA methylation, histone modifications) and addressing each with specialized agents. The composition includes multiple reprogramming agents that work synergistically to target different epigenetic mechanisms simultaneously, thereby improving both effectiveness and efficiency of cellular reprogramming.
Solution Approach 2:
The patent employs a composite composition containing multiple reprogramming agents (including DNA methylation inhibitors, histone modification agents, and transcription factors) combined with protective carriers. This composite approach allows simultaneous modulation of multiple epigenetic pathways, achieving complete epigenetic reversal while maintaining high reprogramming efficiency through synergistic interactions among the components.
2Reliability
If epigenetic changes are reversed to restore youthful gene expression, then cellular function is improved, but genomic instability increases during the reprogramming process
Solution Approach 1:
The patent incorporates protective agents and stabilizing components in the reprogramming composition that preemptively counteract genomic instability. These agents cushion the cellular stress induced by epigenetic reversal, preventing DNA damage and chromosomal abnormalities while allowing successful restoration of youthful gene expression patterns.
Solution Approach 2:
The patent uses intermediary molecules and protective carriers that mediate between the reprogramming agents and cellular DNA. These intermediaries facilitate safe epigenetic modification by controlling the timing and intensity of agent action, thereby restoring gene expression while minimizing direct DNA damage and genomic instability.
3Reliability
If multiple reprogramming agents are used to achieve complete epigenetic reversal, then reprogramming effectiveness is improved, but the complexity of the composition increases
Solution Approach 1:
The patent merges multiple reprogramming agents with different mechanisms of action into a single integrated composition. By combining DNA methylation inhibitors, histone modification agents, and transcription factors in one formulation, the patent achieves complete epigenetic reversal while simplifying the delivery system and reducing the number of separate treatment steps required.
Solution Approach 2:
The patent designs a universal reprogramming composition that simultaneously performs multiple functions: inhibiting DNA methylation, modifying histone structures, and activating transcription factors. This multi-functional approach achieves comprehensive epigenetic reversal through a single composition, reducing overall system complexity despite the multiple biological pathways targeted.
Data Source
AI summary
A cell reprogramming composition and method wherein the composition includes a base molecule, β-nicotinamide mononucleotide, trichostatin A and zwitterionic liposomes and wherein the method includes receiving a cell and reprogramming agents, wherein the reprogramming agents comprise Oct-4, Sox 2 and Klf4, to reprogram the cell to an embryonic state.